What is Epigenic Therapeutics?
Founded in 2021 by a team of distinguished scientists, Epigenic Therapeutics operates at the frontier of biotechnology. The company specializes in the development of advanced gene editing therapies that function by modulating the epigenetic genome rather than relying solely on traditional DNA sequence alteration. This innovative approach offers a sophisticated mechanism for treating complex, rare, and chronic diseases. With a pipeline that spans multiple therapeutic areas, the company is effectively bridging the gap between fundamental genomic research and clinical application. Its market position is bolstered by a strategic focus on high-unmet-need indications, allowing it to carve out a distinct competitive advantage in the rapidly evolving gene therapy landscape.
How much funding has Epigenic Therapeutics raised?
Epigenic Therapeutics has raised a total of $112M across 3 funding rounds:
Other Financing Round
$20M
Series A
$32M
Series B
$60M
Other Financing Round (2022): $20M with participation from Trinity Innovation Fund, TigerYeah Capital, Kingray Capital, Morningside Venture Capital, and Fountainbridge Capital
Series A (2023): $32M led by Morningside Venture Capital, OrbiMed, and Qiming Venture Partners
Series B (2025): $60M supported by IFSC Group, Qiming Venture Partners, and OrbiMed
Key Investors in Epigenic Therapeutics
OrbiMed
A specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms with deep expertise in life sciences.
Qiming Venture Partners
A prominent venture capital firm that invests in innovative companies across technology and healthcare, providing strategic guidance and industry resources to foster long-term growth.
Morningside Venture Capital
A private equity and venture capital firm established in 1986, specializing in early-stage technology company investments with a focus on long-term value creation.
What's next for Epigenic Therapeutics?
With the successful closure of its latest financing round, Epigenic Therapeutics is well-positioned to transition from early-stage research into more advanced clinical development phases. The capital infusion will likely be directed toward scaling its internal R&D capabilities, expanding its product pipeline, and strengthening its intellectual property portfolio. As the company moves toward potential human trials, the focus will shift toward operational excellence and regulatory milestones. The continued support from top-tier venture capital firms suggests a clear path toward future value creation, potentially including strategic partnerships or further expansion into global markets as the company matures into a major enterprise-level player in the biotechnology sector.
See full Epigenic Therapeutics company page
